NEW AUXILIARY THERAPY FOR USE IN THE TREATMENT OF PROSTATE CANCER Russian patent published in 2021 - IPC A61K31/565 A61K45/06 A61P35/00 

FIELD: medicine; oncology.

SUBSTANCE: group of inventions relates to the field of medicine, namely to oncology, and is intended for the treatment of prostate cancer in a patient. A method for the treatment of prostate cancer includes the administration of GnRH agonist or GnRH antagonist and the combined oral administration of esterol at a daily dose from 20 mg to 80 mg for at least 4 weeks. A pharmaceutical dosage form for the treatment of prostate cancer is also presented, adapted for oral administration and containing as the first active ingredient from 20 to 80 mg of esterol and as the second active ingredient GnRH antagonist. In addition, a kit is provided, including the first pharmaceutical composition containing GnRH agonist or GnRH antagonist; the second pharmaceutical composition adapted for oral administration, containing from 20 to 80 mg of esterol; and instructions for the use of the kit for the treatment of prostate cancer.

EFFECT: use of the group of inventions makes it possible to significantly reduce testosterone levels, especially biologically active free testosterone levels, effectively mitigate hypoestrogenic symptoms caused by androgen-deprivation therapy, as well as reduce the risk of arterial cardiovascular diseases.

10 cl, 2 dwg, 1 tbl, 4 ex